Holy Stone Healthcare Co., Ltd. (4194.TWO)
- Previous Close
7.11 - Open
7.10 - Bid 7.02 x --
- Ask 7.21 x --
- Day's Range
7.02 - 7.28 - 52 Week Range
5.50 - 25.00 - Volume
40,014 - Avg. Volume
101,136 - Market Cap (intraday)
1.052B - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
-- - EPS (TTM)
-1.29 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Holy Stone Healthcare Co., Ltd. develops and sells hyaluronic acid related therapeutic products. in Taiwan. The company offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. It also developing IBD98-M, which is in Phase IIa clinical trials for the treatment of inflammatory bowel diseases; and CA102N to treat colorectal cancer. In addition, the company develops ND108E for the treatment of alzheimer's disease; AMD112 which is in pre-clinical stage; and CA102L, a novel and small molecule conjugated therapeutic agent to treat lymphoma and multiple myeloma. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan. Holy Stone Healthcare Co., Ltd. is a subsidiary of Holy Stone Enterprise Co.,Ltd.
www.hshc.com.twRecent News: 4194.TWO
View MorePerformance Overview: 4194.TWO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4194.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4194.TWO
View MoreValuation Measures
Market Cap
1.03B
Enterprise Value
779.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.44
Price/Book (mrq)
3.51
Enterprise Value/Revenue
6.57
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-154.50%
Return on Assets (ttm)
-42.86%
Return on Equity (ttm)
-97.23%
Revenue (ttm)
118.77M
Net Income Avi to Common (ttm)
-183.49M
Diluted EPS (ttm)
-1.29
Balance Sheet and Cash Flow
Total Cash (mrq)
266.68M
Total Debt/Equity (mrq)
4.88%
Levered Free Cash Flow (ttm)
-80.3M